Please login to the form below

Not currently logged in

Daiichi pulls study of patritumab in lung cancer

HER3 inhibitor candidate showed no evidence of efficacy in trial analysis
Daiichi Sankyo

Daiichi Sankyo has halted a late-stage trial of its HER3 inhibitor patritumab after seeing no evidence of efficacy at an interim analysis.

The two-stage trial of patritumab (U3-1287/AMG 888) in combination with Roche's EGFR inhibitor Tarceva (erlotinib) patients with non-small cell lung cancer (NSCLC) was stopped on the advice of the independent data monitoring committee, said the company in a statement.

HER3 (also known as ErbB3) is another member of the HER (human epidermal growth factor receptor) family targeted by established drugs such as Roche's Herceptin (trastuzumab), which binds to HER2. It has been proposed as a potential drug target in cancer since the 1990s but to date no HER3-targeting drugs have been approved for use.

Researchers have hypothesised that inhibiting EGFR and HER3 in tandem could lead to greater efficiency and also overcome resistance to currently available EGFR-directed drugs.

"We are disappointed that this study did not confirm the hypothesis that effective HER3 inhibition in combination with erlotinib would provide clinically relevant tumour growth control in subjects with advanced NSCLC," said Daiichi Sankyo's head of oncology R&D Antoine Yver.

He stressed however that the results do not necessarily undermine the potential role of HER3 as a cancer drug target.

Other companies working on HER3 inhibitors include Merrimack Pharma, whose seribantumab (MM-121) candidate is in phase III, as well as GlaxoSmithKline with GKS2849330 (phase I) and Roche's Genentech unit which has a dual HER3/EGFR inhibitor called MEHD7945A in mid-stage trials.

"This particular result does not directly affect the science of patritumab in other settings," said Yver.

Daiichi Sankyo is also testing patritumab in a phase II trial in head and neck cancer, in combination with Eli Lilly's EGFR inhibitor Erbitux (cetuximab) and platinum-based chemotherapy.

The antibody was developed by Daiichi Sankyo's German subsidiary U3 Pharma, which is being shut down alongside a major reduction in headcount the Japanese drugmaker announced last year. Patritumab is the only drug from U3 that remains in clinical development.

Article by
Phil Taylor

1st June 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...